Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice
The Gram-negative pathogen Pseudomonas aeruginosa is a common cause of pneumonia in hospitalized patients. Its increasing antibiotic resistance and widespread occurrence present a pressing need for vaccines. We previously showed that a P. aeruginosa type III secretion system protein, PopB, elicits a strong Th17 response in mice after intranasal (IN) immunization and confers antibody-independent protection against pneumonia in mice. In the current study, we evaluated the immunogenicity and protective efficacy in mice of the combination of PopB (purified with its chaperone protein PcrH) and OprF/I, an outer membrane hybrid fusion protein, compared with immunization with the proteins individually either by the intranasal (IN) or subcutaneous (SC) routes. Our results show that after vaccination, a Th17 recall response from splenocytes was detected only in mice vaccinated with PopB/PcrH, either alone or in combination with OprF/I. Mice immunized with the combination of PopB/PcrH and OprF/I had enhanced protection in an acute lethal P. aeruginosa pneumonia model, regardless of vaccine route, compared with mice vaccinated with either alone or adjuvant control. Immunization generated IgG titers against the vaccine proteins and whole P. aeruginosa cells. Interestingly, none of these antisera had opsonophagocytic killing activity, but antisera from mice immunized with vaccines containing OprF/I, had the ability to block IFN-γ binding to OprF/I, a known virulence mechanism. Hence, vaccines combining PopB/PcrH with OprF/I that elicit functional antibodies lead to a broadly and potently protective vaccine against P. aeruginosa pulmonary infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Infection and immunity - 90(2022), 10 vom: 20. Okt., Seite e0020322 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shaikh, Mohammad Omar Faruk [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.10.2022 Date Revised 28.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/iai.00203-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345867262 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345867262 | ||
| 003 | DE-627 | ||
| 005 | 20231226030047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/iai.00203-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1152.xml |
| 035 | |a (DE-627)NLM345867262 | ||
| 035 | |a (NLM)36069593 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shaikh, Mohammad Omar Faruk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.10.2022 | ||
| 500 | |a Date Revised 28.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The Gram-negative pathogen Pseudomonas aeruginosa is a common cause of pneumonia in hospitalized patients. Its increasing antibiotic resistance and widespread occurrence present a pressing need for vaccines. We previously showed that a P. aeruginosa type III secretion system protein, PopB, elicits a strong Th17 response in mice after intranasal (IN) immunization and confers antibody-independent protection against pneumonia in mice. In the current study, we evaluated the immunogenicity and protective efficacy in mice of the combination of PopB (purified with its chaperone protein PcrH) and OprF/I, an outer membrane hybrid fusion protein, compared with immunization with the proteins individually either by the intranasal (IN) or subcutaneous (SC) routes. Our results show that after vaccination, a Th17 recall response from splenocytes was detected only in mice vaccinated with PopB/PcrH, either alone or in combination with OprF/I. Mice immunized with the combination of PopB/PcrH and OprF/I had enhanced protection in an acute lethal P. aeruginosa pneumonia model, regardless of vaccine route, compared with mice vaccinated with either alone or adjuvant control. Immunization generated IgG titers against the vaccine proteins and whole P. aeruginosa cells. Interestingly, none of these antisera had opsonophagocytic killing activity, but antisera from mice immunized with vaccines containing OprF/I, had the ability to block IFN-γ binding to OprF/I, a known virulence mechanism. Hence, vaccines combining PopB/PcrH with OprF/I that elicit functional antibodies lead to a broadly and potently protective vaccine against P. aeruginosa pulmonary infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a OprF/I | |
| 650 | 4 | |a PopB | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 4 | |a Th17 | |
| 650 | 4 | |a immunization | |
| 650 | 4 | |a pneumonia | |
| 650 | 7 | |a Pseudomonas Vaccines |2 NLM | |
| 650 | 7 | |a Type III Secretion Systems |2 NLM | |
| 650 | 7 | |a Antibodies, Bacterial |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immune Sera |2 NLM | |
| 700 | 1 | |a Schaefers, Matthew M |e verfasserin |4 aut | |
| 700 | 1 | |a Merakou, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a DiBlasi, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bonney, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Tiffany |e verfasserin |4 aut | |
| 700 | 1 | |a Zurakowski, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kehl, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Tabor, David E |e verfasserin |4 aut | |
| 700 | 1 | |a DiGiandomenico, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Priebe, Gregory P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection and immunity |d 1970 |g 90(2022), 10 vom: 20. Okt., Seite e0020322 |w (DE-627)NLM000004278 |x 0019-9567 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2022 |g number:10 |g day:20 |g month:10 |g pages:e0020322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/iai.00203-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2022 |e 10 |b 20 |c 10 |h e0020322 | ||